

2551-68  
INNX-127-US1



RECEIVED  
APR 01 2003

TECH CENTER 1600/2900

Nixon & Vanderhye P.C. (10/99)  
(Domestic Non-Assigned/Foreign) Page 1

RULE 63 (37 C.F.R. 1.63)  
INVENTORS DECLARATION FOR PATENT APPLICATION  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

As a below named inventor, I hereby declare that my residence, mailing address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (If plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

PURIFIED HEPATITIS C VIRUS ENVELOPE PROTEINS FOR DIAGNOSTIC AND THERAPEUTIC USE

the specification of which (check applicable box(s)):

Is attached hereto  
 was filed on November 29, 2001 as U.S. Application Serial No. 09/995,791 (Atty Dkt. No. 2551-68)  
 was filed as PCT International application No. \_\_\_\_\_ on \_\_\_\_\_  
and (if applicable to U.S. or PCT application) was amended on January 11, 2002

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose to the Patent Office all information known to me to be material to patentability as defined in 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application:

Priority Foreign Application(s):

Application Number	Country	Day/Month/Year Filed
I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.		
Application Number	Date/Month/Year Filed	
60/304,194	December 1, 2000	
60/260,669	January 11, 2001	
60/315,768	August 30, 2001	

I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT International applications listed above or below:

Prior U.S./PCT Application(s): Application Serial No.	Day/Month/Year Filed	Status: patented pending, abandoned
--	----------------------	--

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. And on behalf of the owner(s) hereof, I hereby appoint NIXON & VANDERHYE P.C., 1100 North Glebe Rd., 8th Floor, Arlington, VA 22201-4714, telephone number (703) 816-4000 (to whom all communications are to be directed), and the following attorneys thereof (of the same address) individually and collectively owner's/owners' attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Larry S. Nixon, 25640; Arthur R. Crawford, 25327; James T. Hosmer, 30184; Robert W. Faris, 31352; Richard G. Besha, 22770; Mark E. Nusbaum, 32348; Michael J. Keenan, 32106; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Mitchard, 29009; Duane M. Byers, 33363; Jeffry H. Nelson, 30481; John R. Lastova, 33149; H. Warren Burnam, Jr. 29366; Mary J. Wilson, 32955; J. Scott Davidson, 33489; Alan M. Kagen, 36178; Robert A. Molan, 29834; B. J. Sadoff, 36683; James D. Berquist, 34776; Updeep S. Gill, 37334; Michael J. Shea, 34725; Donald L. Jackson, 41090; Michelle N. Lester, 32331; Frank P. Presta, 19828; Joseph S. Presta, 35329; Joseph A. Rho, 37515; Raymond Y. Mah, 41426; Chris Comuntzia, 31097; Gary T. Tanigawa, 43180. I also authorize Nixon & Vanderhye to delete any attorney names/numbers no longer with the firm and to act and rely solely on instructions directly communicated from the person, assignee, attorney, firm, or other organization sending instructions to Nixon & Vanderhye on behalf of the owner(s).

1. Inventor's Signature:

Inventor:

Maertens

Date:

17 December 2002

Belgian

(citizenship)

Residence: (city)

Brugge 3

MI

(last)

Belgium

Mailing Address:

Zilversparrenstraat 64, Brugge 3, Belgium

B-8310

2. Inventor's Signature:

Inventor:

Depla

Date:

13 December 2002

Belgium

(citizenship)

Residence: (city)

Destelbergen

MI

(last)

Belgium

Mailing Address:

Burgstraat 56, Destelbergen, Belgium

9070

See attached sheet(s) for additional inventor(s) information!!

3. Inventor's Signature:

Inventor:

Residence: (city)

Mailing Address:

(Zip Code)

Fornis  
(first)

MI

Bosman

(last)

(state/country) Belgium

Opwijk  
Hulst 165, Opwijk, Belgium  
B-1745

Date:

18-12-2002

Belgian  
(citizenship)

RECEIVED

APR 01 2003

TECH CENTER 1600/2900

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of

MAERTENS et al.

Atty. Ref.: 2551-68

Serial No. 09/995,791

Group: 1646

Filed: November 29, 2001

Examiner:

For: PURIFIED HEPATITIS C VIRUS ENVELOPE PROTEINS  
FOR DIAGNOSTIC AND THERAPEUTIC USE

\* \* \* \* \*

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**STATEMENT UNDER RULE 48(a)**

I, Marie-Ange BUYSE, Merelbeke, Belgium state that the error naming me as an inventor of the above-identified application occurred without deceptive intention on my part.

  
\_\_\_\_\_  
Marie-Ange BUYSE

16 dec 2002

Date

RECEIVED  
APR 01 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

MAERTENS et al.

Atty. Ref.: 2551-68

Serial No. 09/995,791

Group: 1646

Filed: November 29, 2001

Examiner:

For: PURIFIED HEPATITIS C VIRUS ENVELOPE PROTEINS  
FOR DIAGNOSTIC AND THERAPEUTIC USE

\* \* \* \* \*

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

STATEMENT UNDER RULE 48(a)

I, Erik DEPLA, Destelbergen, Belgium state that the error in not naming me as an inventor of the above-identified application occurred without deceptive intention on my part.



Erik DEPLA

13 December 2002.

Date

RECEIVED

APR 01 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

MAERTENS et al.

Atty. Ref.: 2551-68

Serial No. 09/995,791

Group: 1646

Filed: November 29, 2001

Examiner:

For: PURIFIED HEPATITIS C VIRUS ENVELOPE PROTEINS  
FOR DIAGNOSTIC AND THERAPEUTIC USE

\* \* \* \* \*

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

CONSENT OF THE ASSIGNEE TO  
CORRECTION OF INVENTORSHIP

INNOGENETICS N.V., having a principal place business at Industriepark Zwijnaarde 7, Box 4, B-9052 Ghent, Belgium, verifies through its duly authorized representative that it is the assignee of the above-identified application by way of an Assignment executed by Geert MAERTENS, and Fons BOSMAN, recorded in the United States Patent and Trademark Office on July 26, 2002, at Reel 013129, Frame(s) 0222, and by way of an assignment executed by Erik DEPLA, copy attached and separately submitted for recordation in the United States Patent & Trademark Office along with the present paper.

I represent that I am authorized to execute this document on behalf of INNOGENETICS N.V. I further certify that to the best of my knowledge and belief the title of this invention is in INNOGENETICS N.V.

MAERTENS et al.  
Serial No. 09/995,791

- INNOGENETICS N.V. being assignee of the above-identified application, hereby consents to the correction of inventorship of the above-identified application to delete Marie-Ange BUYSE as an inventor and add Erik DEPLA as an inventor.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Signed this 17<sup>th</sup> day of December, 2002.

(Signature)   
Print Name: Philippe Archinard

Chief Executive Officer

Print Title